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Abstract 
Backgrund/Aim. In recent decades noninvasive methods 
for the assessment and monitoring of liver fibrosis have 
been developed and evaluated in numerous chronic liver 
diseases. The aim of this study was to evaluate the 
diagnostic accuracy of noninvasive markers for fibrosis 
assessment transient elastography (TE) and biochemical 
markers using liver biopsy as reference in patients with 
primary biliary cirrhosis (PBC). Methods. One hundred 
and twenty-two patients underwent both liver biopsy and 
blood tests on the same day and TE in a month following 
the biopsy and the tests. Liver biopsies were reviewed by a 
single pathologist using the METAVIR scoring system for 
assessment of liver fibrosis. Aspartate aminotransferase 
(AST), platelet ratio index (APRI), Forns scores, AST and 
alanine transaminase (ALT) ratio and TE were compared 
with liver fibrosis stage in order to determine the best non-
invasive marker of liver fibrosis. Results. There was a sta-
tistically significant difference (p < 0.05) for the APRI score, 
Forns index and TE according to stages of liver fibrosis. TE 
showed superior diagnostic performance when compared to 
other surrogate markers of liver fibrosis that were investi-
gated. Optimal cut-off for TE were 4.25 and 5.9 kPa for di-
agnosing the presence of fibrosis and distinguishing 
mild/moderate and advanced stages of fibrosis respectively. 
The areas under the receiver operating characteristic (AU-
ROC) of TE were 0.963 and 0.865, respectively. Conclu-
sion. Based on our investigation the APRI score, Forns in-
dex and TE adequately predict fibrosis stage in patients with 
primary biliary cirrhosis, but the most sensitive and specific 
parameter appears to be TE. Using noninvasive markers 
and methods in the evaluation of patients in daily clinical 
practice may reduce, but not eliminate, the need for invasive 
diagnostic procedures. 
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Apstrakt 
Uvod/Cilj. Prethodnih decenija otkrivene su 
neinvanzivne metode za procenu i praćenje fibroze jetre 
kod hroničnih bolesti jetre. Cilj ove studije bila je procena 
dijagnostičke preciznosti neinvanzivnih metoda za 
određivanje fibroze jetre [tranzijentna elastografija (TE) i 
biohemijski markeri], pri čemu je kao zlatni standard 
korišćena biopsija jetre kod bolesnika sa primarnom 
bilijarnom cirozom. Metode. U studiju su bila uključena 
122 bolesnika kod kojih su istog dana urađene biohemijske 
analize i biopsija jetre, a mesec dana kasnije urađena je TE. 
Za procenu fibroze jetre korišćen je METAVIR skor, a sve 
preparate biopsija proverio je jedan patolog. APRI skor – 
odnos aspartat aminotransferaze (AST) i trombocita, 
Forns indeks, odnos AST i alanin transaminaze (ALT) i 
TE poređene su sa stepenom fiboze jetre dobijene na 
osnovu biopsija jetre u cilju dobijanja najboljeg 
neinvanzivnog markera u proceni fibroze jetre. Rezultati. 
Dokazana je statistička značajnost (p < 0.05) za APRI 
skor, Forns indeks i TE za procenu stepena fibroze jetre. 
TE je imala najbolji dijagnostički učinak u poređenju sa 
ostalim markerima koje smo istraživali. Optimalne 
granične vrednosti za TE bile su 4.25 i 5.9 kPa za 
dijagnozu fibroze jetre i razlikovanje slabe/umerene i 
uznapredovale fibroze. Površina ispod krive operativnih 
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karakteristka (AUROC) za TE bila je 0.963 i 0.865. 
Zaključak. Na osnovu rezultata ove studije proizilazili  su 
APRI skor, Forns indeks i TE adekvatni dijagnostički 
markeri fibroze jetre kod bolesnika sa primarnom 
biijarnom cirozom, ali je  TE najsenzitivniji i najspecifičniji 
parametar. Koristeći neinvanzivne parametre i metode u 
svakodnevnoj kliničkoj praksi može se smanjiti, ali ne i 




jetra, ciroza; biopsija; krv, hemijske analize; biološki 




Primary biliary cirrhosis (PBC) is a slowly progressing 
autoimmune disease of the liver that primarily affects middle 
aged women with an annual incidence ranging from 0.7 to 49 
cases per million 1. Histologically, PBC is characterized by 
portal inflammation and immune-mediated destruction of 
intrahepatic bile ducts resulting in further hepatic damage, 
fibrosis and liver cirrhosis 2. 
Liver biopsy remains the gold standard for the liver 
fibrosis assessment, but it is an invasive and expensive 
procedure, associated with a low, but negligible risk of 
complications and mortality 3, 4. Moreover, the accuracy of 
liver biopsy in assessing fibrosis has been questioned 
because of sampling errors as well as intraobserver and 
interobserver variability 5. 
In the last decade, numerous noninvasive methods for 
the assessment of liver fibrosis were developed and 
evaluated. Ideally, the test should be reliable, fast, 
reproducible, easily applicable in every day clinical practice 
as well as acceptable for patients and reliable for both 
prognosis and staging of liver disease. 
However, most of these methods have been extensively 
studied in viral hepatitis, but not much has been done 
regarding patients with PBC 6–9. The aim of this work was to 
compare the diagnosis accuracy of liver stiffens – transient 
elastography (TE) with simple and routinely available blood 
markers: aspartate aminotransferase (AST) to platelet ratio 
index (APRI), the Forns index, AST to alanine transaminase 




This study included 122 prospectively selected patients 
who were diagnosed with PBC at the Clinic for 
Gastroenterology and Hepatology, Clinical Center of Serbia, 
Belgrade from June 2009 to January 2011. The diagnosis of 
PBC was based on at least 2 out of 3 criteria including 
elevated serum alkaline phosphatase (ALP), presence of serum 
antimitochondrial antibodies (AMA) and liver histology 
consistent with PBC. The diagnosis was confirmed on the 
basis of the presence of a typical clinical picture, biochemical 
(elevated ALP ≥ 1.5 times the upper normal value for over 24 
weeks) and serological markers (AMA in serum ≥ 1:40) as 
well as characteristic histological findings on liver biopsy in 
absence of extrahepatic biliary obstruction. Histological 
staging was classified ranging from portal tract inflammation 
with predominantly lymphoplasmacytic infiltrates and septal 
and interlobar bile duct loss (stage I) to cirrhosis (stage IV). 
On the same day, each patient underwent blood testing and 
liver biopsy, while liver stiffness measurements (LSM) using 
the TE technique were carried out during the following month. 
Exclusion criteria were presence of ascites, obesity (body mass 
index > 30 kg/m2), hepatocellular carcinoma, hepatothropic 
virus infection, history of alcohol abuse, and all other causes 
of chronic liver injuries. 
Surrogate markers of liver fibrosis 
The following serum parameters were examined by 
venous blood sampling and were processed in our hospital 
labaratory: AST measured in (IU/L), ALT mesured in IU/L, 
gamma-glutamyl transpeptidase (GGT) in IU/L, ALP in 
IU/L, platelets (Pt ×109/L), total bilirubin measured in 
µmol/L, albumins in g/L, cholesterol measured in mmol/L, 
and prothrombin time (PT – normal range 9.5–13.5 s). On 
the basis of these biological tests, we calculated the 
following scores for predicting liver fibrosis: AST/ALT 
ratio, APRI score = [(AST/upper limit of normal AST) ×100] 
/ number of platelets (109/L) [9, 17] and Forns score = 7.811 
- 3.131 × ln [number of platelets (109/L)] × 0.781 ln [GGT 
(U/L)] + 3.467 × ln [age (years)] – 0.014 [cholesterol 
(mg/dL)] 10. 
Liver biopsy 
Percutaneous liver biopsy was performed on each patient 
and specimens were routinely processed. Only specimens at 
least 2 cm long were selected and used for this investigation. 
Adequate biopsy specimens were obtained from 122 patients. 
Sections were analyzed independently by a single experienced 
pathologist unfamiliar with the patients clinical details and 
results of the noninvasive methods. Liver fibrosis was evaluated 
semiquantitatively according to the METAVIR scoring system. 
Fibrosis was scored on a scale of 0–4 as follows: F0 = no 
fibrosis; F1 = portal fibrosis without septa; F2 = portal fibrosis 
and few septa, F3 = numerous septa without cirrhosis; F4 = 
cirrhosis. Histological evaluation included grade of 
inflammation, ductopenia, bile duct inflammation and 
destruction, cholestasis and ductal proliferation. 
Liver stiffness measurement 
Liver stiffness was measured by transient elastography 
using a FibroScan® (EchoSens, Paris, France) equipped with 
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an M probe. The measurements were obtained from the right 
lobe of the liver. The patients lay in the dorsal decubitus 
position with the right arm maximally abducted, through the 
intercostal spaces between 25 mm and 65 mm from the skin 
surface. Only examination with 10 valid measurements at a 
success rate of at least 60% (ratio of the number of 
successful attempts over the total number of attempts) and an 
interquartile range less than 30% were considered reliable 
and kept for statistical analyses. The final result was the 
median of 10 valid measurements and was expressed in kPa. 
Statistical analysis 
We used methods of descriptive and analytical 
statistics. Basic descriptive statistics included means, 
standard deviations, ranges and percentages. Normal 
distribution of continuous data was tested using the 
Kolgomorov-Smirnov test. Analysis of variance (ANOVA) 
or Kruskal- Wallis test were used for assessment of 
differences among groups. The diagnostic performance of 
noninvasive liver assessment methods were performed by 
receiver operating characteristic (ROC) analysis. Statistical 
analysis was performed using the Statistical Package for 
Social Sciences (SPSS®, version 14.0). 
Ethics 
This study was approved by the Ethical Committee of 
our hospital and all patients signed informed consent before 
inclusion into the study. 
Results 
Patients 
From the total of 122 patients, 106 (86.5%) of the 
patients were women with a mean age of 57.40 ± 8.92 years. 
Their clinical details are summarized in Table 1. All the 
patients were treated with UDCA (ursodeoxycholic acid) 
after determining the diagnosis of PBC, 23 (19.2%) patients 
were without fibrosis (F0), 38 (30.8%)  patients had mild 
fibrosis (F1), 12 (9.6%) patients moderate (F2), 16 (13.5%) 
patients advanced fibrosis (F3), and 33 (26.9%) patients  had 
liver cirrhosis (F4). 
Noninvasive serum parameters 
The values of noninvasive serum markers were 
compared for each histological fibrosis stage (Table 2). We 
found a difference among APRI, the Forns index and TE 
Table 1 
Baseline clinical, biochemical and histological characteristics of patients with liver fibrosis (n = 122) 
Variables ґ ± SD (mediana, min-max) 
Age, (years) 57.4 ± 8.9 (58; 42–75) 
Alkaline phosphatase (IU/L) 137.9 ± 87.6 (98; 28–351) 
Gamma-glutamyl transpeptidase  (IU/L) 123.1 ± 142.0 (68; 13–603) 
Aspartate aminotransferase (AST), (IU/L) 48.0 ± 30.3 (46; 14–176) 
Alanine aminotransferase (ALT), (IU/L) 50.8 ± 27.7 (46; 18–158) 
Bilirubin (µmol/L) 13.8 ± 8.3 (11.2; 3.5–36.5) 
Platelets (109/L) 209.1 ± 87.2 (212; 52–422) 
Albumine (g/L) 39.5 ± 4.6 (40; 28–51) 
Protrombin time (PT), s 90.2 ± 18.2 (93; 43–125) 
Cholesterol (mmol/L) 5.1 ± 1.4 (5.43; 2.33–8.73) 
AST/ALT 0.9 ± 0.3 (0.97; 0.41–1.70) 
AST platelet ratio index 0.6 ± 0.7 (0.40; 0.10–2.60) 
Forns index 6.0 ± 2.1 (5.47; 2.75–10.85) 
Transient elastography (kPa) 9.6 ± 6.9 (6.8; 3.2–30.7) 
METAVIR scoring system, n (%) 
F0 23 (19.2%) 
F1 38 (30.8%) 
F2 12 (9.6%) 
F3 16 (13.5%) 
F4 33 (26.9%) 
ґ ± SE – mean ± standard deviation; n (%) – number (percentage) of patients. 
Table 2 
Surrogate markers of liver fibrosis 
Variables 
METAVIR Score 
(ґ ± SD) 
F0 
n = 23 
F1 
n = 38 
F2 
n = 12 
F3 
n = 16 
F4 
n = 33 
AST/ALTa (IU/L) 0.9 ± 0.2 1.0 ± 0.3 0.8 ± 0.2 0.9 ± 0.2 1.0 ± 0.3 
APRI*b (IU/L/109) 0.2 ± 0.1 0.5 ± 0.6 0.4 ± 0.2 0.9 ± 0.9 1.0 ± 0.7 
Forns index*a 4.3 ± 0.9 5.8 ± 2.0 5.4 ± 0.5 7.0 ± 3.0 7.4 ± 2.4 
TE (kPa) *b 5.5 ± 0.2 6.4 ± 2.1 9.3 ± 4.3 10.8 ± 3.9 17.7 ± 7.8 
*Statistically significant differences; aOne way ANOVA; bKruskal -Wallis test; AST – aspartate aminotransferase;
ALT – alanine aminotransferase; APRI – AST platelets index; TE – transient elastography. 
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according to stages of liver fibrosis. AST∕ALT ratio did not 
show any significant difference. For these parameters, we 
calculated sensitivity, specificity and Area under the receiver 
operating characteristic (AUROC), as presented in Table 3 and 
Figure 1, as well as best cut-off values for determining the 
presence of liver fibrosis (Table 4 and Figure 2). A cut-off value 
of 0.255 for the APRI score as well as the Forns index cut-off 
value of 4.168 were statistically significant for predicting 
existence of liver fibrosis. Also, we recognized a statistically 
significant possibility for distinguishing patients having mild-to-
moderate fibrosis (F1 or F2) and advanced fibrosis (F3 or F4) as 
presented in Tables 5 and 6, and Figures 3 and 4, respectively. 
Table 3 
Area under the reciever operating characteristic (AUROC) curve for surrogate markers of liver fibrosis (fibrosis: no vs. yes) 
Surrogate markers of  
liver fibrosis AUROC 
Asymp  
significance 
95% Confidence interval  
(bound: lower-upper) 
AST/ALT (IU/L) 0.588 0.390 0.419–0.758 
APRI (IU/L/109) 0.782 0.006* 0.649–0.915 
Forns index 0.806 0.003* 0.685–0.927 
TE (kPa) 0.963 0.000* 0.000–1.000 
*Statistically significant; AST – aspartate aminotransferase; ALT – alanine aminotransferase; APRI – AST-platelet 
index; TE – transient elastography. 
Table 4 
Sensitivity and specifity for surrogate markers of liver fibrosis (fibrosis: no vs. yes) 
Surrogate markers of 
liver fibrosis Cut-off Sensitivity  Specifity  
Asymp  
significance AUC (95% CI) 
AST/ALT 0.917 0.571 0.600 0.403 0.586 (0.388–0.783) 
APRI 0.255 0.810 0.600 0.046* 0.705 (0.510–0.899) 
Forns index 4.168 0.881 0.500 0.063 0.690 (0.486–0.894) 
TE (kPa) 7.250 0.929 1.000 0.000* 0.964 (0.001–0.999) 




Fig. 1 – ROC curve for surrogate markers of liver fibrosis. 
ROC – receiver operating characteristic.  
For abbreviations see Table 3. 
 
Fig. 2 – ROC curve for surrogate markers of liver fibrosis 
with cut-off. 
For abbreviations see Table 3. 
 
Table 5 
Area under the curve (AUC) for surrogate markers of liver fibrosis (fibrosis: stage I–II vs. III–IV) 




95% Confidence interval  
(bound: lower-upper) 
AST/ALT 0.428 0.480 0.235–0.621 
APRI 0.601 0.323 0.396–0.806 
Forns index 0.676 0.084 0.495–0.858 
TE (kPa) 0.865 0.000* 0.747–0.984 
For other abbreviations see Table 3;*statistically significant. 
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Transient elastography findings 
The values of TE ranged from 3.2 to 30.7 kPa, median 
6.8 kPa, mean 9.6 ± 7.0 kPa. A statistically significant 
difference was found between TE and fibrosis stage of liver 
disease (Tables 2 and 3). TE was found to be accurate in 
diagnosing the presence of liver fibrosis. For cut-off value of 
7.25 kPa, it showed 92.9% of sensitivity and 100% of 
specificity (AUROC 0.964). These results were the best 
when compared to other surrogate markers of fibrosis. The 
optimal cut-off values for distinguishing patients having 
mild-to-moderate fibrosis (F1 or F2) and advanced fibrosis 
(F3 or F4) were 9.9, with 91.7% of sensitivity and 69.2% of 
specificity and AUROC 0.865 (Tables 5 and 6, and Figures 3 
and 4, respectively). These results were superior in 
comparison to other surrogate markers for liver fibrosis. 
Discussion 
Primary biliary cirrhosis occurs worldwide with a 
female to male ratio of 9:1. The diagnosis of PBC is based 
on criteria which include elevation of liver enzymes, positive 
AMA test and positive liver biopsy. Widespread use of 
screening laboratory tests has led to an increase of PBC 
diagnosis frequency while the disease is in asymptomatic 
stage. Liver biopsy has been considered to be a gold standard 
for the diagnosis of PBC, even though fibrosis in PBC is 
patchy in distribution within the parenchyma and many 
patients are reluctant to experience repeated biopsies which 
limits  our ability to monitor disease progression and effects 
of treatment. 
In recent decades, a lot has been done in order to find 
adequate noninvasive markers for the assessment of liver 
fibrosis. The ideal characteristics of such markers would be: 
specificity for liver fibrosis; providing measurement of: stage 
of fibrosis, fibrogenesis activity; not influenced by 
comorbidities (e.g. renal, reticulo-endothelial); known half-
life; known excretion route; sensitivity and reproduciblity 11. 
Direct markers are markers of fibrogenesis, measurable in 
peripheral blood as a direct expression of either the 
deposition or removal of ECM in liver (several 
glycoproteins, the collagen family, the collagenases and their 
inhibitors and a number of cytokines connected with the 
fibrogenetic process). Indirect markers of liver fibrosis are 
routinely performed blood tests. The diagnostic performance 
of most direct and indirect markers of liver fibrosis has been 
widely investigated in all common etiological forms of 
chronic liver diseases, but not as much in patients with PBC. 
Unfortunately, there are currently no serum surrogate 
markers of liver fibrosis routinely recommended in PBC. 
Our study is the PBC specific and it was conducted on 
particulary homogenous study population recruited from a 
single center. On the same day, each patient involved in this 
Table 6 
Sensitivity and specifity for surrogate markers of liver fibrosis (fibrosis: stage F – I-II vs. F – III-IV) 
Surrogate markers of 
liver fibrosis Cut-off Sensitivity Specifity 
Asymp 
significance AUC (95% CI) 
AST/ALT 1.010 0.500 0.615 0.572 0.558 (0.358–0.757) 
APRI 0.297 0.667 0.577 0.233 0.622 (0.429–0.814) 
Forns index 5.460 0.750 0.654 0.048* 0.702 (0.522–0.882) 
TE (kPa) 9.900 0.917 0.692 0.003* 0.804 (0.659–0.950) 
AUC – area under the curve; for other abbreviations see Table 3; *statistically significant. 
Fig. 3 – ROC for surrogate markers of liver fibrosis, 
fibrosis: stage F – I-II vs. F – III-IV. 
For abbreviations see Table 3. 
Fig. 4 – ROC curve for surrogate markers of liver fibrosis: 
stage F – I-II vs. F – III-IV with cut-off. 
For abbreviations see Table 3. 
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study, underwent blood tests and liver biopsy, while TE was 
performed in the following month. 
In this study we investigeted 3 noninvasive markers, 
available and routinely used in every day clinical practice. 
The AST∕ALT ratio, although widely used, did not show any 
statistical significance. 
As far as we know, there are few published studies 
assessing the APRI score in the PBC patients 7, 9, 11, 12.  Obara 
et al. 13 showed that the APRI score can predict fibrosis F ≥ 2 
(AUROC O.77) in patients with nonviral liver diseases. In 
our study that was not the case. The APRI score did not 
show statistically significant difference in distinguishing 
patients with mild-to-moderate fibrosis and advanced 
fibrosis, perhaps because the study population was not the 
same. In our study, the APRI score showed statistically 
significant difference in presence and stages of liver fibrosis 
(AUROC 0.782). A cut-off value of 0.255 (sensitivity 81%, 
specificity 60%, AUROC 0.705) could distinguish patients 
who did not have (F0) and those who had liver fibrosis (F1). 
In our study, the Forns index, although not so widely 
used and investigated in cholestatic liver disease, did 
correlate with the presence and stages of liver fibrosis 
(AUROC 0.806). The optimal cut-off for F ≥ 3 was 5.46 
(sensitivity 75%, specificity 65.4%, AUROC 0.702). 
In 2012, a retrospective study was conducted in China 14. It 
included 73 patients with PBC and assessed the diagnostic value 
of noninvasive markers of liver fibrosis in PBC based on 
coventional laboratory results (platelet count, serum 
cholinesterase, albumin, HDL-C and prothrombin time activity). 
According to this study, the established noninvasive model 
could accurately distinguish pathological changes of early stage 
of PBC (stage I–II) from advanced stage (III–IV). 
TE is a novel, noninvasive method used for evaluation 
of fibrosis in chronic liver disease. Published meta analyses 
have shown that TE is a reliable method for diagnosing liver 
cirrhosis 15–17. The effectiveness of TE is well established in 
patients with chronic hepatitis C 18, but it has not been used 
widely in assessing  fibrosis in nonviral liver disease. In the 
past few years, a very small number of studies investigating 
the effectiveness of TE in evaluation of patients with PBC 
was published.  
A study conducted in Spain including 80 patients with 
PBC, showed statistically significant correlation between TE 
and liver biopsies 6, while another study from Italy conducted on 
120 patients with PBC proved that TE is a simple, reliable and 
useful method for assessing liver fibrosis 7. 
Coprechot et al. 8 assessed 140 patients with PBC in 
order to define the diagnostic performance of TE and the 
time course of changes of fibrosis progression as well as 
prognosis in a monitored cohort of ursodeoxycholic acid 
(UDCA)–treated patients followed up for five years. Their 
results showed that TE is one of the best current surrogate 
markers of liver fibrosis in PBC. In a five year period while 
on the treatment, liver stiffness appeared to remain stable in 
most noncirrhotic patients, whereas it significantly increased 
in patients with cirrhosis. The study did not find evidence 
that combination of TE and noninvasive markers 
significantly improved diagnostic accuracy. 
Present findings strongly suggest that monitoring of TE 
in patients with PBC provides significant prognostic 
information in comparison with classic serum prognostic 
markers and that it may be used to predict outcome and 
select high-risk patients for further clinical trials 8. 
In addition, TE efficiency was validated by comparing it 
to other imaging techniques. Friedrich-Rust et al. 9 compared 
TE, magnetic resonance imaging (MRI) and spectroscopy 
MRI, and serum markers in 45 PBC patients. They showed 
that MRI and TE can be used with comparable results for the 
assessment of liver fibrosis in patients with PBC and that the 
two techniques seem to supplement each other. 
In our study, TE appears to be the best surrogate marker 
for assessment of liver fibrosis in patients with PBC. When 
compared to other noninvasive liver markers, TE was shown 
to have the highest sensitivity and specificity. 
Conclusion 
Assessment of liver fibrosis by TE is an easy, rapid, 
effective, and safe noninvasive method with high sensitivity 
and specificity. Using noninvasive markers and methods in 
evaluating patients in daily clinical practice may reduce, but 
still not eliminate, the need for invasive diagnostic 
procedures. 
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